JANX Quote, Financials, Valuation and Earnings

Amgen has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 6.9%. Janux Therapeutics's return on equity of -11.37% beat Amgen's return on equity of 66.87%.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 196.3%. On the other hand Amgen has an analysts' consensus of $317.64 which suggests that it could grow by 11.07%. Given that Janux Therapeutics has higher upside potential than Amgen, analysts believe Janux Therapeutics is more attractive than Amgen.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.19% to investors and pays a quarterly dividend of $2.38 per share. Janux Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Amgen quarterly revenues of $9.1B. Janux Therapeutics's net income of -$20.2M is lower than Amgen's net income of $627M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 37.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 118.62x versus 4.62x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -87.96%. Janux Therapeutics's return on equity of -11.37% beat Fortress Biotech's return on equity of --.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 196.3%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 950.23%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Janux Therapeutics's net income of -$20.2M is lower than Fortress Biotech's net income of -$12.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 118.62x versus 0.41x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Hepion Pharmaceuticals has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Hepion Pharmaceuticals's return on equity of --.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 196.3%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 355350.24%. Given that Hepion Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.389%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Janux Therapeutics's net income of -$20.2M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 118.62x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 22.15%. Janux Therapeutics's return on equity of -11.37% beat Innoviva's return on equity of 3.44%.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 196.3%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 8.45%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.553%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Innoviva quarterly revenues of $91.8M. Janux Therapeutics's net income of -$20.2M is lower than Innoviva's net income of $20.3M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Innoviva's PE ratio is 92.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 118.62x versus 3.88x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.